Article Text

Download PDFPDF
What exactly are we doing to improve low lung cancer survival in the United Kingdom?
  1. Eric Lim1,
  2. Sanjay Popat2
  1. 1Department of Thoracic Surgery, The Royal Brompton Hospital, London, UK
  2. 2Department of Medicine, The Royal Marsden Hospital, London, UK
  1. Correspondence to Eric Lim, The Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK; e.lim{at}rbht.nhs.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Low lung cancer survival

When one is presented with a blinded report of survival rates for lung cancer across developed countries, how can one identify the result for the UK? Exactly, choose the one with the poorest outcome. You would be correct more often than not (unless Denmark was included).

In 2007 and 2009, the EUROCARE Group published results of cancer survival identifying the UK among the countries with the lowest survival rates for lung cancer in Europe.1 ,2 As expected, this was met with a degree of outrage and attribution of poor UK results to differences in population characteristics and quality of reporting. An articulate defence launched by Moller et al hypothesised ‘less favourable stage distribution in the United Kingdom’ as the likely explanation for poor UK outcomes compared with other European countries compounded by suspicion of ‘incomplete ascertainment of deaths’ in certain countries reporting high survival results.3 Apart from population characteristics and quality of reporting, socioeconomic status within Europe (a surrogate for healthcare spending for the management of lung cancer) has also been cited rendering such comparisons inequitable.4

This week in Thorax, the International Cancer Benchmarking Partnership published survivorship of patients with lung cancer in six ‘wealthy countries’, namely, Australia, Canada, Denmark, Norway, Sweden, and of course, the UK between 1995 and 2007.5 The socioeconomic status differences have been redressed and stage adjustment rectified. At last, the UK has a chance to perform on an equal footing! So, with baited breath, you ask, …

View Full Text

Footnotes

  • Contributors EL and SP contributed to writing the editorial.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Lung cancer
    Sarah Walters Camille Maringe Michel P Coleman Michael D Peake John Butler Nicholas Young Stefan Bergström Louise Hanna Erik Jakobsen Karl Kölbeck Stein Sundstrøm Gerda Engholm Anna Gavin Marianne L Gjerstorff Juanita Hatcher Tom Børge Johannesen Karen M Linklater Colleen E McGahan John Steward Elizabeth Tracey Donna Turner Michael A Richards Bernard Rachet the ICBP Module 1 Working Group Søren Brostrøm Heather Bryant David Currow Anna Gavin Gunilla Gunnarsson Jane Hanson Todd Harper Stein Kaasa Michael A Richards Michael Sherar Bob Thomas Jan Adolfsson Ole Andersen Heather Bryant Andy Coldman Dhali Dhaliwal Gerda Engholm Anna Gavin David Forman Marianne L Gjerstorff Juanita Hatcher Charlotte Hosbond Tom B Johannesen Mats Lambe Karen M Linklater Loraine Marrett Colleen E McGahan John McLaughlin David Meechan Richard Middleton Kamini Milnes Diane Nishri Nicola Quin Linda Rabenek Carol Russell Janey Shin John Steward Elizabeth Tracey Donna Turner Stefan Bergström Michael Boyer John Butler William Evans Louise Hanna Erik Jakobsen Karl Kölbeck Jason Lester Jonathan McAleese Michael D Peake Stein Sundstrøm Nicholas Young Ian Williamson Sarah Walters Camille Maringe Michel P Coleman Rachet Bernard
  • Airwaves
    Andrew Bush Ian Pavord